[Figure 1](#pone-0093312-g001){ref-type="fig"}, [Figure 6](#pone-0093312-g002){ref-type="fig"}, and Equation 1 have been corrected for better readability.

![Protocol for administering orlistat to tumor-bearing mice.\
Mice were transplanted DL cells (1x105cells/0.5 ml PBS) on day 0 following administration of Vehicle alone (control) or containing orlistat 240mg/kg body weight/day up to day 14 post tumor transplantation. On day 16 BMC were harvested from femurs.](pone.0093312.g001){#pone-0093312-g001}

![BMDM obtained from BMC of orlistat-administered groups display M1 Mφ phenotype.\
BMDM differentiated from BMC of control or orlistat-administered tumor-bearing mice were incubated *in* *vitro* for 24h in medium alone or containing IFN- γ (100IU/ml) + LPS (10ng/ml) followed by estimation of NO (a), indicated cytokines by ELISA in culture supernatant (b), assay of ROS expression (d,e), phagocytosis (c), BMDM-mediated tumoricidal activity (f,g) and expression of cell surface functional markers: CD11c and TLR2 (h). Values shown in (a,b,e,f,g) mean ± SD of three independent experiments done in triplicate.\**p\<0*.*05* *vs*. values of respective control. \*\#p*\<*0.05 vs. values for orlistat and LPS + IFN-γ treated control groups. Arrows indicates increased phagocytosis (c), expression of ROS (d) and CD11c & TLR-2 (h) in BMDM of orlistat group treated with IFN-γ + LPS.](pone.0093312.g002){#pone-0093312-g002}

[Figure 1](#pone-0093312-g001){ref-type="fig"} is incorrect. The authors have provided a corrected version here.

[Figure 6](#pone-0093312-g002){ref-type="fig"} is incorrect. The authors have provided a corrected version here.

Equation 1 is incorrect. The authors have provided a corrected version here.
